Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$76.53 - $131.49
Previous CloseN/A
Volume316.50K
Average Volume (3M)940.75K
Market Cap
$21.13B
Enterprise Value$10.67B
Total Cash (Recent Filing)-€172.35M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 05, 2025EPS Estimate
-2.23Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-3.02
Shares Outstanding239,970,810
10 Day Avg. Volume1,064,965
30 Day Avg. Volume940,752
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.62
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$139.56Price Target Upside60.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBNT327 combined with chemotherapy demonstrated an 87.5% objective response rate and superior median progression-free and overall survival in extensive-stage small cell lung cancer patients compared to benchmark trials.
Company FinancialsBioNTech ended the year with approximately €17.4 billion in cash, cash equivalents, and marketable securities, indicating strong financial health.
Financial PerformanceBioNTech recorded net earnings per diluted share of €1.08, surpassing the previous forecast of €0.04 per share.
Bears Say
Data Maturity ConcernsThere remains a key concern on whether the preliminary signals, especially overall survival, can hold as the data is still highly immature.
Financial OutlookThe projection for a full-year net loss per diluted share increased to €4.87 from the prior estimate of €4.64, raising concerns about future profitability.
---
Ownership Overview
― Insiders
4.58% Mutual Funds
13.91% Other Institutional Investors
80.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $21.13B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is May 05, 2025 which is in 27 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Mar 10, 2025. The company reported $1.184 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.694.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.534 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -2.23.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 239,970,810 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of $1.184 in its last earnings report, beating expectations of $0.49. Following the earnings report the stock price went down -3.153%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
---
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$139.56 (60.75% Upside)
$139.56 (60.75% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 548.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $137.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.10%
12-Months-Change
Fundamentals
Return on Equity
-3.38%
Trailing 12-Months
Asset Growth
-8.20%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
---
BNTX Company Deck
---
BNTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook for BioNTech. While there are significant advancements in their oncology pipeline and strategic acquisitions like Biotheus, challenges remain with declining COVID-19 vaccine revenues and ongoing legal costs. Financial losses for 2024 also highlight some operational difficulties. The sentiment is balanced between optimism for future growth and caution due to current financial and operational challenges.Read More>---
BNTX Stock 12 Month Forecast
Average Price Target
$139.56
▲(60.75% Upside)
Technical Analysis
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-10.02%
initiated a buy rating last month
Copying William Maughan's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -10.02% per trade.
---